Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)

NCT ID: NCT07176689

Last Updated: 2026-01-15

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE4
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-09-17
• Study Completion Date: 2031-03-30

Brief Summary

This study is being conducted to study how nirogacestat may affect the ovarian function of adult premenopausal women with progressing desmoid tumors/aggressive fibromatosis.

Detailed Description

Desmoid tumors, also referred to as aggressive fibromatosis, are rare, locally invasive, slow growing soft tissue tumors. Although considered benign because of their inability to metastasize, desmoid tumors can cause significant morbidity and occasionally mortality in patients.

Nirogacestat is a tumor inhibitor that works by slowing or stopping the growth of tumor cells. Nirogacestat is a tablet taken by mouth and has been approved in the USA for adult patients with progressing desmoid tumors who require systemic treatment.

This is an open-label study to characterize the incidence and ovarian function recovery rates of ovarian toxicity (OT) events and to evaluate the efficacy, safety, and tolerability of nirogacestat in postpubertal and premenopausal females with desmoid tumors (DT).

Conditions

Desmoid Tumor; Aggressive Fibromatosis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Nirogacestat

Nirogacestat 150 mg by mouth, twice daily

Group Type: EXPERIMENTAL

Nirogacestat

Intervention Type: DRUG

Nirogacestat oral tablet

Interventions

Nirogacestat

Nirogacestat oral tablet

Intervention Type: DRUG

Other Intervention Names

PF-03084014; Ogsiveo

Eligibility Criteria

Inclusion Criteria

• Participant is female, postpubertal aged ≥18 and ≤40 years of age at the time of signing the informed consent and premenopausal at baseline. Premenopausal is defined as meeting all of the following: Estradiol >30 pg/mL. Follicle-stimulating hormone (FSH) <40 IU/L. Regular menses (e.g., menstrual cycle length of 21 to 35 days) for at least 3 menstrual cycles prior to signing informed consent
• Participant uses 1 highly effective non-hormonal contraceptive method, has a negative pregnancy test prior to first dose of study treatment), is not breastfeeding, agrees to not harvest or donate eggs for at least 90 days prior to and during the study
• Participant has histologically confirmed DT/AF with symptomatic or progressive disease requiring systemic treatment
• Participant has an Eastern Cooperative Oncology Group (ECOG) performance status ≤2 at screening
• Participant has adequate organ and bone marrow function.

Exclusion Criteria

• Participant has known malabsorption syndrome or preexisting gastrointestinal conditions that may impair absorption of nirogacestat
• Participant has experienced any of the following within 6 months of signing informed consent: clinically significant cardiac disease (New York Heart Association Class III or IV), myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, or symptomatic pulmonary embolism.
• Participant has had lymphoma, leukemia, or any malignancy within the past 5 years at the time of informed consent, except for any locally recurring cancer that has been treated curatively (e.g., resected basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast), with no evidence of metastatic disease for 3 years at the time of informed consent.
• Participant has known hepatic impairment
• Participant previously received or is currently receiving gamma secretase inhibitors or anti-Notch antibody therapy
• Participant is currently using any treatment for DT/AF including tyrosine kinase inhibitors (TKIs) or any investigational treatment 28 days (or 5 half-lives, whichever is longer) prior to the first dose of study treatment
• Participant is currently using or anticipates using food or drugs that are known strong/moderate cytochrome P450 (CYP) 3A4 inhibitors, or strong CYP3A inducers within 14 days prior to the first dose of study treatment.
• Participant has a history of polycystic ovary syndrome, hypothalamic amenorrhea, severe endometriosis involving ovaries, family history of primary ovarian insufficiency, any chromosomal abnormality, mutation, gene variant or medical condition associated with early/premature menopause, including a history of OT while on a TKI
• Participant is currently using or has used hormonal contraception or ovarian suppression within 90 days prior to first dose of study treatment
• Participant has a history of heavy tobacco smoking (≥20 pack years) or is a current smoker (>1 pack per day)
• Participant has experienced other severe acute or chronic medical or psychiatric conditions within 1 year of signing informed consent.
• Participant is unable to comply with study related procedures (including, but not limited to, the completion of a menstrual diary and electronic patient-reported outcomes and ability to return to clinic for hormone level blood draws timed to the menstrual cycle (days 1-5)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 40 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

SpringWorks Therapeutics, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Winette van der Graff, MD

Role: PRINCIPAL_INVESTIGATOR

The Netherlands Cancer Institute

Locations

Cliniques Universitaires Saint-Luc (CUSL)

Brussels, , Belgium

Site Status: RECRUITING

Universitätsklinikum Mannheim, Mannheim Cancer Center

Mannheim, , Germany

Site Status: RECRUITING

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" IRCCS IRST. S.r.l.

Meldola, Forli-Cesena, Italy

Site Status: RECRUITING

Fondazione del Piemonte per l'Oncologia Istituto di Candiolo IRCCS

Candiolo, Torino, Italy

Site Status: RECRUITING

Istituto Nazionale Tumori I.R.C.C.S- Fondazione G. Pascale

Napoli, , Italy

Site Status: RECRUITING

Fondazione Policlinico Unversitario Campus Bio-Medico di Roma

Roma, , Italy

Site Status: RECRUITING

Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL)

Amsterdam, , Netherlands

Site Status: RECRUITING

LUMC

Leiden, , Netherlands

Site Status: RECRUITING

Hospital de la Santa Creu i Sant Pau

Barcelona, , Spain

Site Status: RECRUITING

Hospital General Universitario Gregorio Maranon

Madrid, , Spain

Site Status: RECRUITING

Hospital Universitario Jimenez Diaz

Madrid, , Spain

Site Status: RECRUITING

Hospital General Universitario Gregorio Maranon

Madrid, , Spain

Site Status: RECRUITING

Hospital Universitario La Paz

Madrid, , Spain

Site Status: RECRUITING

Hospital Universitario y Politecnico La Fe

Valencia, , Spain

Site Status: RECRUITING

Hospital Universitario Miguel Servet

Zaragoza, , Spain

Site Status: RECRUITING

Cambridge University Hospitals NHS Foundation Trust

Cambridge, , United Kingdom

Site Status: RECRUITING

University College London Hospitals NHS Foundation Trust

London, , United Kingdom

Site Status: RECRUITING

The Royal Marsden NHS Foundation Trust

London, , United Kingdom

Site Status: RECRUITING

The Christie NHS Foundation Trust

Manchester, , United Kingdom

Site Status: RECRUITING

Countries

Belgium; Germany; Italy; Netherlands; Spain; United Kingdom

Central Contacts

Nicole H Leedom

Role: CONTACT

clinical@springworkstx.com

984-204-8065

Facility Contacts

Filomena Mazzeo, MD

Role: primary

Filomena.mazzeo@saintluc.uclouvain.be

Bernd Kasper, MD

Role: primary

bernd.kasper@umm.de

Lorena Gurrieri, MD

Role: primary

Lorena.gurrieri@irst.emr.it

Giovanni Grignani, MD

Role: primary

giovanni.grignani@ircc.it

Salvatore Tafuto, MD

Role: primary

s.tafuto@istitutotumori.na.it

Bruno Vincenzi, MD

Role: primary

b.vincenzi@policlinicocampus.it

Winette van der Graaf, MD

Role: primary

w.vd.graaf@nki.nl

André Johan Gelderblom, MD

Role: primary

A.J.Gelderblom@lumc.nl

Ana Sebio Garcia, MD

Role: primary

asebio@santpau.cat

Rosa Alvarez, MD

Role: primary

rosa.alvarez.al@gmail.com

Nadia Hindi, MD

Role: primary

nhindi@atbsarc.org

Aranzazu Manzano, MD

Role: primary

aranzazu.manzano@salud.madrid.org

Andres Redondo Sanchez, MD

Role: primary

aredondo12@gmail.com

Roberto Diaz, MD

Role: primary

diaz_rob@gva.es

Javier Martinez Trufero, MD

Role: primary

jmtrufero@seom.org

Han Hsi Wong, MD

Role: primary

han.wong@nhs.net

Vasilios Karavasilis, MD

Role: primary

vasilios.karavasilis@nhs.net

Charlotte Benson, MD

Role: primary

charlotte.benson@rmh.nhs.uk

Alexander Lee, MD

Role: primary

alexander.lee1@nhs.net

Other Identifiers

2024-515215-21-00

Identifier Type: CTIS

Identifier Source: secondary_id

NIR-DT-401

Identifier Type: -

Identifier Source: org_study_id